Oxford BioMedica PLC (OXB) - Total Liabilities
Based on the latest financial reports, Oxford BioMedica PLC (OXB) has total liabilities worth GBX183.59 Million GBX (≈ $22.34K USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how much of Oxford BioMedica PLC's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Oxford BioMedica PLC - Total Liabilities Trend (1996–2024)
This chart illustrates how Oxford BioMedica PLC's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see OXB asset base.
Oxford BioMedica PLC Competitors by Total Liabilities
The table below lists competitors of Oxford BioMedica PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Renoworks Software Inc
V:RW
|
Canada | CA$2.32 Million |
|
Close Brothers Group plc
LSE:CBG
|
UK | GBX10.82 Billion |
|
Nexalin Technology Inc.
NASDAQ:NXL
|
USA | $808.36K |
|
Companhia Paranaense de Energia Pref ADR
NYSE:ELP
|
USA | $36.10 Billion |
|
Ladangbaja Murni PT Tbk
JK:LABA
|
Indonesia | Rp31.52 Billion |
|
Lomiko Metals Inc
V:LMR
|
Canada | CA$3.57 Million |
|
Jatcorp Ltd
AU:JAT
|
Australia | AU$18.64 Million |
|
HydrogenPro AS
OL:HYPRO
|
Norway | Nkr108.74 Million |
Liability Composition Analysis (1996–2024)
This chart breaks down Oxford BioMedica PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See OXB net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.89 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 5.61 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.85 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Oxford BioMedica PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Oxford BioMedica PLC (1996–2024)
The table below shows the annual total liabilities of Oxford BioMedica PLC from 1996 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | GBX171.16 Million ≈ $20.82K |
-1.92% |
| 2023-12-31 | GBX174.51 Million ≈ $21.23K |
-22.09% |
| 2022-12-31 | GBX223.99 Million ≈ $27.25K |
+348.95% |
| 2021-12-31 | GBX49.89 Million ≈ $6.07K |
-29.91% |
| 2020-12-31 | GBX71.18 Million ≈ $8.66K |
+50.50% |
| 2019-12-31 | GBX47.30 Million ≈ $5.75K |
-39.10% |
| 2018-12-31 | GBX77.66 Million ≈ $9.45K |
+31.06% |
| 2017-12-31 | GBX59.26 Million ≈ $7.21K |
+33.68% |
| 2016-12-31 | GBX44.33 Million ≈ $5.39K |
+8.23% |
| 2015-12-31 | GBX40.96 Million ≈ $4.98K |
+280.43% |
| 2014-12-31 | GBX10.77 Million ≈ $1.31K |
+126.84% |
| 2013-12-31 | GBX4.75 Million ≈ $577.45 |
-0.71% |
| 2012-12-31 | GBX4.78 Million ≈ $581.59 |
-42.58% |
| 2011-12-31 | GBX8.32 Million ≈ $1.01K |
-40.71% |
| 2010-12-31 | GBX14.04 Million ≈ $1.71K |
-38.88% |
| 2009-12-31 | GBX22.97 Million ≈ $2.80K |
+15.73% |
| 2008-12-31 | GBX19.85 Million ≈ $2.42K |
-32.09% |
| 2007-12-31 | GBX29.23 Million ≈ $3.56K |
+436.53% |
| 2006-12-31 | GBX5.45 Million ≈ $662.86 |
+106.29% |
| 2005-12-31 | GBX2.64 Million ≈ $321.33 |
+19.77% |
| 2004-12-31 | GBX2.21 Million ≈ $268.28 |
+46.90% |
| 2003-12-31 | GBX1.50 Million ≈ $182.63 |
+19.13% |
| 2002-12-31 | GBX1.26 Million ≈ $153.31 |
-28.25% |
| 2001-12-31 | GBX1.76 Million ≈ $213.65 |
+31.04% |
| 2000-12-31 | GBX1.34 Million ≈ $163.04 |
+67.29% |
| 1999-12-31 | GBX801.00K ≈ $97.46 |
+66.88% |
| 1998-12-31 | GBX480.00K ≈ $58.40 |
+8.84% |
| 1997-12-31 | GBX441.00K ≈ $53.66 |
+250.00% |
| 1996-12-31 | GBX126.00K ≈ $15.33 |
0.00% |
| 1996-09-30 | GBX126.00K ≈ $15.33 |
-- |
About Oxford BioMedica PLC
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The… Read more